<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01327378</url>
  </required_header>
  <id_info>
    <org_study_id>H-C-2009-007</org_study_id>
    <nct_id>NCT01327378</nct_id>
  </id_info>
  <brief_title>The Incretin Effect in Patients With Kidney Impairment</brief_title>
  <acronym>UREMINC</acronym>
  <official_title>The Incretin Effect in Non-diabetic Patients With Severe Renal Impairment Depending on Chronic Dialysis Treatment</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Gentofte, Copenhagen</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Rigshospitalet, Denmark</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Copenhagen</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University Hospital, Gentofte, Copenhagen</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The current study explores the incretin effect; a central mechanism of sugar metabolism.&#xD;
      People with type 2 diabetes have a markedly reduced incretin effect, while the incretin&#xD;
      effect never has been studied in patients with severe chronic renal failure. Non-diabetic&#xD;
      patients with severe kidney failure and patients with diabetes and normal kidney function&#xD;
      share several pathophysiological traits, including decreased sensitivity to insulin, fasting&#xD;
      hyperinsulinaemia and impaired beta cell function. The investigators expect the incretin&#xD;
      effect to be affected in patients with chronic renal failure without diabetes, which in time&#xD;
      can result in therapeutic changes in this group of patients.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The novel and original aspect of this investigator initiated study is the focus on incretin&#xD;
      (patho)physiology in an uraemic milieu. In this first of 5 substudies (separate notification&#xD;
      and registration) the investigators explore the incretin effect. Our hypothesis is that it is&#xD;
      impaired in non-diabetic patients in chronic dialysis treatment.&#xD;
&#xD;
      The prevalence of type 2 diabetes mellitus (T2DM) is rapidly increasing worldwide. In&#xD;
      addition to reduced insulin sensitivity and beta cell dysfunction, T2DM is characterized by a&#xD;
      severely impaired incretin effect. The incretin effect refers to the insulinotropic action of&#xD;
      the nutrient-released incretin hormones glucagon-like peptide-1 (GLP-1) and glucose-dependent&#xD;
      insulinotropic peptide (GIP). Both hormones are secreted from intestinal endocrine mucosal&#xD;
      cells. The incretin effect is defined as the difference in insulin secretory responses&#xD;
      between oral and isoglycaemic intravenous (iv) glucose challenges. In healthy individuals it&#xD;
      accounts for as much as 70% of insulin secreted in response to oral glucose, whereas patients&#xD;
      with T2DM exhibit an incretin effect in the range of 0 to 30%. The incretin hormone GLP-1 has&#xD;
      a potent blood glucose-lowering effect in patients with T2DM. However, following secretion of&#xD;
      GLP-1, the ubiquitous enzyme dipeptidyl peptidase-4 (DPP-4) rapidly cleaves the hormone, by&#xD;
      which it is completely inactivated. This has formed the basis for new pharmacological agents&#xD;
      blocking DPP-4 (DPP-4 inhibitors) or DPP-4 resistant GLP-1 receptor agonists. Long-term&#xD;
      treatment has showed positive effect on glycaemic control and risk factors of cardiovascular&#xD;
      diseases in patients with T2DM.&#xD;
&#xD;
      These effects may be applicable also in patients with end-stage renal disease (ESRD) because&#xD;
      patients with T2DM and normal kidney function and non-diabetic patients with ESRD show&#xD;
      several identical characteristics. These include decreased insulin sensitivity,&#xD;
      hyperinsulinaemia and impaired beta cell function. The incretin effect has only to a small&#xD;
      extent been investigated in patients with ESRD.&#xD;
&#xD;
      The single most frequent cause of ESRD and need of chronic maintenance dialysis is diabetic&#xD;
      nephropathy. In the U.S. more than 50% of patients in dialysis have diabetes compared with&#xD;
      about 23% in Denmark. The life expectancy of dialysis patients with T2DM is severely reduced&#xD;
      with a median survival of 2 to 4 years and there is no treatment documented to significantly&#xD;
      improve this poor prognosis. The most common cause of death in this group of patients is&#xD;
      related to cardiovascular disease that seems to result from death of causes different from&#xD;
      classical atherosclerosis. So far intervention directed towards hypertension, dyslipidaemia&#xD;
      and other classical risk factors have showed divergent and primarily negative results.&#xD;
&#xD;
      There is therefore an unmet medical need to find new treatments to protect these patients&#xD;
      from cardiovascular disease and premature death.&#xD;
&#xD;
      Improving the glycaemic control using incretin-based therapies has the potential to meet this&#xD;
      medical need. The incretin hormones and their metabolites are however to a large extent&#xD;
      excreted by the kidneys and this may lead to problems (or benefits!) when administered to&#xD;
      patients without kidney function or with severely reduced kidney function. The present&#xD;
      knowledge about the incretin effect and incretin hormone physiology as well as&#xD;
      pharmacokinetics, clinical effects and side effects of GLP-1 analogues in patients with&#xD;
      reduced kidney function is limited and the few studies available are predominantly confined&#xD;
      to patients with only mild or moderately reduced kidney function. The investigators will&#xD;
      explorer basic and pharmacologic aspects in patients with severe reduced kidney function&#xD;
      depending on chronic maintenance dialysis treatment. Before any potential treatment can be&#xD;
      initiated, the investigators need basic information on how the incretin system is affected by&#xD;
      an uraemic milieu. Current and succeeding substudies will provide us with that information.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2009</start_date>
  <completion_date type="Actual">October 2010</completion_date>
  <primary_completion_date type="Actual">October 2010</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Cross-Sectional</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Incretin effect</measure>
    <time_frame>Minimum 3 days and maximum 3 weeks between the two examination days. Cross-sectional design. No follow up.</time_frame>
    <description>IE= 100%*(iAUC,OGTT - iAUC,IIGI)/iAUC,OGTT Assessed at two separate examination days. Day 1: Oral glucose tolerance test (OGTT), Day 2: Intravenous isoglycaemic glucose infusion (IIGI).&#xD;
Data will be presented when all analyses have been performed. Estimated in May 2011.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Gastric-induced glucose disposal (GIGD)</measure>
    <time_frame>Minimum 3 days and maximum 3 weeks between the two examination days. Cross-sectional design. No follow up.</time_frame>
    <description>GIGD=100%*(glucose,OGTT-glucose,IIGI)/glucose,OGTT) Assessed at two separate examination days. Day 1: Oral glucose tolerance test (OGTT), Day 2: Intravenous isoglycaemic glucose infusion (IIGI).&#xD;
Data will be presented when all analyses have been performed. Estimated in May 2011.</description>
  </secondary_outcome>
  <number_of_groups>3</number_of_groups>
  <enrollment type="Actual">30</enrollment>
  <condition>Renal Insufficiency, Chronic</condition>
  <arm_group>
    <arm_group_label>Dialysis, normal glucose tolerance</arm_group_label>
    <description>Chronic dialysis treatment, N=10 OGTT,120 min &lt; 7.8 mmol/L</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dialysis, impaired glucose tolerance</arm_group_label>
    <description>Chronic dialysis treatment, N=10 OGTT,120 min 7.7&lt;11.1 mmol/L</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control, normal glucose tolerance</arm_group_label>
    <description>Healthy Control subjects, N=10 OGTT,120 min &lt;7.8 mmol/L</description>
  </arm_group>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Plasma (10 ml per participant)&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        3 groups&#xD;
&#xD;
          1. Chronic hemodialysis treatment. Normal glucose tolerance (NGT). N=10&#xD;
&#xD;
          2. Chronic hemodialysis treatment. Impaired glucose tolerance (IGT). N=10&#xD;
&#xD;
          3. Healthy control subjects. Normal glucose tolerance. N=10&#xD;
&#xD;
        Glucose tolerance is evaluated at the screeningday. A 75 gram oral glucose tolerance test&#xD;
        (OGTT) is performed and the 120 minute value sets the glucose tolerance. NGT: &lt; 7.8 mmol/L,&#xD;
        IGT: &gt; 7.7 mmol/L and &lt; 11.1 mmol/L (according to WHO guidelines).&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Male or female; age: 18 - 90 years&#xD;
&#xD;
          -  CKD stage 5 (CrCL &lt; 15 ml/min) in chronic haemodialysis (minimum 3 months)&#xD;
&#xD;
          -  NGT or IGT (diagnosed according to WHO criteria)&#xD;
&#xD;
          -  Body mass index 18.5 - 28 kg/m2&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Type 1 or 2 diabetes mellitus&#xD;
&#xD;
          -  Pancreatitis&#xD;
&#xD;
          -  Medication with influence on insulin secretion and/or glucose metabolism&#xD;
&#xD;
          -  Previous or actual malignancy&#xD;
&#xD;
          -  Inflammatory bowel disease&#xD;
&#xD;
          -  Congestive heart failure (NYHA III-IV)&#xD;
&#xD;
          -  Previous bowel resection&#xD;
&#xD;
          -  Severe hypertension&#xD;
&#xD;
          -  Impaired liver function&#xD;
&#xD;
          -  Haemoglobin &lt; 6.5 mmol/L&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bo Feldt-Rasmussen, Prof, DMSc</last_name>
    <role>Study Director</role>
    <affiliation>Department of Nephrology, Rigshospitalet, University of Copenhagen, Denmark</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Department of Nephrology P 2131, Rigshospitalet</name>
      <address>
        <city>Copenhagen Ã˜</city>
        <zip>2100</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <verification_date>June 2010</verification_date>
  <study_first_submitted>March 29, 2011</study_first_submitted>
  <study_first_submitted_qc>March 31, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 1, 2011</study_first_posted>
  <last_update_submitted>March 31, 2011</last_update_submitted>
  <last_update_submitted_qc>March 31, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 1, 2011</last_update_posted>
  <responsible_party>
    <name_title>Thomas Idorn/M.D. PhD student</name_title>
    <organization>Department of Nephrology, Rigshospitalet, University of Copenhagen, Denmark</organization>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Renal Insufficiency</mesh_term>
    <mesh_term>Renal Insufficiency, Chronic</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

